Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan clinical oncology group study 9505

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1347-1355

  Itoh, K ^a   Ohtsu, T ^a   Fukuda, H ^b   Sasaki, Y ^a   Ogura, M ^c   Morishima, Y ^c   Chou, T ^d   Aikawa, K ^e   Uike, N ^f   Mizorogi, F ^g   Ohno, T ^h   Ikeda, S ⁱ   Sai, T ^j   Taniwaki, M ^k   Kawano, F ^l   Niimi, M ^b   Hotta, T ^m   Shimoyama, M ⁿ   Tobinai, K ^o  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Iwaki Kyoritsu General Hospital   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e TOKAI UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j NIIGATA CANCER CENTER HOSPITAL   (Japan)

^k HOKKAIDO CANCER CENTER   (Japan)

^l National Hospital Organization   (Japan)

^m JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ OTSU RED CROSS HOSPITAL   (Japan)

^o Sasebo Shiritsu Sogo Hospital   (Japan)

more..

Author keywords

Biweekly CHOP; Dose intensity; Dose escalated CHOP; G CSF; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; FEMALE; FREQUENCY ANALYSIS; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; JAPAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036739093     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf287     Document Type: Article

References (40)

1. Armitage J. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-1030.
2. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349.
3. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
4. Cooper IA, Wolf MM, Robertson TI et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769-778.
5. Montserrat E, García-Conde J, Viñolas N et al. CHOP vs ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish cooperative group for the study of hematological malignancies treatment, Spanish Society of Hematology). Eur J Haematol 1996; 57: 377-383.
6. Jerkeman M, Anderson H, Cavallin-Ståhl E et al. CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Ann Oncol 1999; 10: 1079-1086.
7. Messori A, Vaiani M, Trippoli S et al. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303-307.
8. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977.
9. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
10. Shipp MA, Abeloff MD, Antman KH et al. International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-429.
11. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH 87-2 protocol-A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
12. The international non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
13. Shipp MA, Neuberg D, Janicek M et al. High-dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995; 13: 2916-2923.
14. Santoro A, Balzarotti M, Tondini C et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 519-525.
15. Itoh K, Ohtsu T, Wakita H et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11: 1241-1247.
16. Tanosaki R, Okamoto S, Akatsuka N et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 1994; 74: 1939-1944.
17. Pronzato P, Lionetto R, Botto F, et al. High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study. Br J Cancer 1998; 78: 777-780.
18. Truemper L, Schmits R, Kloess M et al. High CHOEP: Primary treatment of aggressive non-Hodgkin's lymphoma (NHL) in patients <60 years with time and dose escalated chemotherapy and growth factor support: A phase I/II study of the German high grade NHL study group. Blood 1999; 94 (Suppl 1): 99a (Abstr 433).
19. The non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 42: 2112-2135.
20. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-257.
21. Grading of toxicity. In Wittes RE (ed): Manual of Oncologic Therapeutics 1991/1992. Philadelphia, PA: Lippencott 1991; 445-448.
22. Itoh K, Ohtsu T, Sasaki Y et al. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 38: 521-532.
23. Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med 1994; 13: 417-429.
24. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
25. Epelbaum R, Faraggi D, Ben-Arie Y et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990; 66: 1124-1129.
26. Meyer RM, Hryniuk WM, Goodyear MDE. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1991; 9: 339-347.
27. Lepage E, Gisselbrecht C, Haioun C et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol 1993; 4: 651-656.
28. Meyer RM, Quirt IC, Skillings JR et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 1770-1776.
29. Meyer RM, Browman GP, Samosh ML et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386-2393.
30. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
31. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 1998; 16: 2796-2802.
32. Verdonck LF, van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-1051.
33. Kaiser U, Uebelacker I, Havemann K. High dose chemotherapy with autologous stem cell transplantation in aggressive NHL: analysis of a randomized multicenter study. Ann Oncol 1999; 10 (Suppl 3): 76 (Abstr 262).
34. Milpied N, Deconninck E, Foussard CC et al. Frontline high dose chemotherapy with autologous stem cell transplantation is not superior to CHOP regimen for adult patients with non IPI high risk intermediate or high grade NHL: results of a randomized trial by the GOELAMS. Ann Oncol 1999; 10 (Suppl 3): 77 (Abstr 266).
35. Martelli M, Gherlinzoni F, Zinzani PL et al. Early autologous stem cell transplantation as first-line therapy in poor prognosis non-Hodgkin's lymphoma (NHL): an Italian randomized trial. Ann Oncol 1999; 10 (Suppl 3): 78 (Abstr 271).
36. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
37. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
38. Coiffier B, Lepage E, Gaulard P et al. Prognostic factors affecting the efficacy of rituximab plus CHOP (R-CHOP) therapy in elderly patients with diffuse large B-cell lymphoma (DLCL): results of a randomized GELA trial. Proc Am Soc Clin Oncol 2001; 20: 283a (Abstr 1131).
39. Stockmeyer B, Dechant M, van Egmond M et al. Triggering FC α-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000; 165: 5954-5961.
40. Niitsu N, Iki S, Muroi K et al. Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96. Br J Cancer 1997; 76: 1661-1666.